TIDMYGEN
RNS Number : 2980K
Yourgene Health PLC
01 September 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Notice of AGM and Annual Report 2021
Investor presentation
Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, announces that the Notice
of Annual General Meeting ("AGM") and Form of Proxy will shortly be
available on the Company's website at:
www.yourgene-health.com/investors/key-documents/shareholder-communications
and are being posted to those shareholders who have opted out of
electronic communications.
The Annual Report and Accounts for the year ended 31 March 2021,
published on 11 August 2021, are available at:
www.yourgene-health.com/investors/key-documents/financial-reports
AGM and Investor presentation
The Company's AGM will be held at 4:00pm (BST) on Tuesday 28
September 2021, and will be held as a hybrid meeting
electronically, via the Investor Meet Company platform ("IMC") and
physically, at the Company's offices Citylabs 1.0, Nelson Street,
Manchester M13 9NQ. The AGM will take place with minimal
face-to-face contact.
The Company has been monitoring closely the evolving situation
relating to the Coronavirus (COVID-19) pandemic, including the
recent easing of restrictions on travel and public gatherings and
social distancing. While the Company values opportunity to meet
shareholders at the AGM, that might not be possible or desirable,
notwithstanding the relaxation in current guidelines. The priority
of the Board at this time is the health, safety and wellbeing of
all Shareholders and Directors.
At least two share-owning Directors will be present so as to
constitute the quorum of two Shareholders required for the AGM
proceedings to be valid, and all other existing and potential
shareholders will be able to take part in the meeting virtually,
via IMC platform.
The Company's CEO, Lyn Rees, will also provide shareholders with
a short presentation after the formal business of the AGM concludes
and there will be an opportunity for investors to ask questions.
Investors can sign up to IMC for free and add to meet Yourgene
Health plc via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
Investors who already follow Yourgene on the IMC platform will
automatically be invited.
Shareholders taking part via the IMC platform will not be able
to speak or vote on the AGM resolutions. Shareholders should
carefully consider whether or not it is appropriate to attend the
AGM in person. Shareholders are strongly encouraged to exercise
their voting rights by completing and submitting a Form of Proxy.
It is highly recommended that Shareholders submit their Form of
Proxy as early as possible to ensure that their votes are counted
at the AGM. Shareholders are strongly encouraged to appoint the
Chairman as your proxy to ensure that each Shareholder's vote will
be counted in the event of restrictions on shareholders and proxies
attending the AGM in person.
Any shareholder wishing to attend in person must register in
advance by contacting the Company at investors@yourgene-health.com
. Shareholders should be aware that the Company may require to
limit or restrict the number of people attending in person or
cancel attendance in person at short notice, if circumstances
change or maximum capacity it reached. The Company may also put in
place other safety and security measures as a condition of
admission to the AGM to align with UK government guidelines or as a
safety measure at the time of the meeting, where appropriate.
However, any shareholders who have questions they would like
answered can send them to yourgene@walbrookpr.com in advance of the
meeting and they will be responded to promptly or can be submitted
pre-event via your IMC dashboard up until 9am the day before the
meeting or at any time during the live presentation.
If you wish to submit a proxy vote for this meeting, please
submit your vote online at www.signalshares.com. For your vote to
be valid please ensure that it is received by no later than 4.00pm
on Friday 24 September 2021. Alternatively, should you wish to vote
via the CREST system, please see the instructions in the Notice of
Meeting.
The situation in respect of COVID-19 may change rapidly and
Shareholders should note that further changes may need to be put in
place at short notice in relation to the AGM. Any updates to the
position will be announced by the Company and will also be included
on the Company's website at www.yourgene-health.com .
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genomic services and
technologies. The group works in partnership with global leaders in
DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and infectious diseases.
The Group's flagship in vitro diagnostic products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation
platforms, powered by Ranger(R) Technology, the Yourgene
LightBench(R) and Yourgene QS250, ideal for cell-free DNA
applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network
equipped to be a full life-cycle partner for clinical, research and
pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new
products and services. In addition, Yourgene Genomic Services
offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with
facilities in Taipei, Singapore, the US and Canada, and is listed
on the London Stock Exchange's AIM market under the ticker "YGEN".
Follow us on LinkedIn and Twitter .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDFLFXFVLEBBX
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024